A Phase 3 interventional study of RSVpreF vaccine and Placebp in Respiratory Syncytial Virus, sponsored by Pfizer. Completed at 14 sites in South Africa. Open to participants aged 0 Years to 49 Years. Per ClinicalTrials.gov, last updated 2026-07-02.
Sponsored by Pfizer · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Respiratory Tract Infections by Pfizer — 2 open to participants now, 3 under way, 2 of them phase 3. Respiratory Tract Infections · Pfizer.
Among the 23 studies in Respiratory Tract Infections by Pfizer, this one is the 7th largest by enrollment of the 18 interventional ones that give a count, is one of 4 that started in 2024, is one of 7 in phase 3, and was the 17th registered.
753 studies on the registry are indexed under Respiratory Tract Infections; 114 are open to participants now.
Browse Respiratory Tract Infections studies →2 of the 23 studies in Respiratory Tract Infections by Pfizer are open now, in 12 countries. Recruiting first, the newest first:
Pfizer · Sites in United States, Argentina, Belgium and 15 more countries
Ages 18+
Pfizer · Sites in United States, Argentina, Belgium and 16 more countries
Ages 12+
By country, each count listing its studies:
Of the 74 Respiratory Tract Infections studies recruiting now, 35 (47%) set no upper age limit and 31 (42%) stop at 75 or younger; 34 take children under 18; 25 take healthy volunteers.
This study: 0 Years to 49 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 681 is above the median of 200 across 542 interventional studies indexed under Respiratory Tract Infections.
Median enrollment 309 across the 18 interventional studies, 421 across the 5 observational. Of the 18 that completed or were terminated, 13 (72%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
2 of the studies in Respiratory Tract Infections by Pfizer that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 23 studies in Respiratory Tract Infections by Pfizer, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to learn about the safety and immune activity of the RSVpreF vaccine. It will be studied in infants born to mothers living with HIV. These infants may have higher chances of getting sick or dying due to RSV infection. Respiratory Syncytial Virus (RSV) is a common type of virus (germ) that can cause severe illness (airway diseases), where medical help is needed. Vaccines help your body make antibodies which help fight against diseases. The antibodies are substances your body uses to fight off an infection. The antibodies can be passed to the infant through the placenta of the mother.
The study will look at the safety, tolerability, and immune activity in mothers and their infants.
This study is seeking pregnant women who are:
Participants will either receive:
Pregnant participants will be involved in the study from:
Key Inclusion Criteria - Maternal Participants
Key Inclusion Criteria - Infant Participants
Key Exclusion Criteria - Maternal Participants
Key Exclusion Criteria - Infant Participants
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RSV vaccine (RSVpreF)
Biological: RSVpreF vaccine
Placebo
Biological: Placebp
RSVpreF vaccine
Placebo
Percentage of Maternal Participants With Prespecified Local Reactions Within 7 Days After Vaccination
Local reactions included redness, swelling, and pain at injection site and were recorded in electronic diary (e-diary). Redness and swelling were measured by the maternal participant and recorded in measuring device units (mdu) in the e-diary (range: 1 to 21). 1 mdu = 0.5 centimetre (cm). Redness and swelling were graded as mild (\>2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm), severe (\>10.0 cm) and grade 4 (necrosis or exfoliative dermatitis for redness and necrosis for swelling). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and grade 4 (emergency room visit or hospitalization for severe pain at the injection site). Grade 4 reactions were classified by the investigator or medically qualified designee.
Time frame: From Day 1 to Day 7 after vaccination
Percentage of Maternal Participants With Prespecified Systemic Events Within 7 Days After Vaccination
Systemic events included fever, fatigue, headache, nausea, muscle pain, joint pain, vomiting and diarrhea and were recorded by participants in the e-diary. Fever was defined as an oral temperature greater than or equal to (\>=) 38.0 degree Celsius (C) and classified as mild (38.0 to 38.4 degree C), moderate (38.5 to 38.9 degree C), severe (39.0 to 40.0 degree C) and grade 4 (\>40.0 degree C). Headache, nausea, fatigue, muscle pain and joint pain were graded as mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily activity). Vomiting: mild (1-2 times in 24 hours \[H\]), moderate (\>2 times in 24 H), severe (required intravenous \[IV\] hydration). Diarrhea: mild (2-3 loose stools in 24 H), moderate (4-5 loose stools in 24 H), severe (\>=6 loose stools in 24 H). For all systemic events except fever, Grade 4= emergency room visit or hospitalization. Grade 4 events were classified by investigator or medically qualified designee.
Time frame: From Day 1 to Day 7 after vaccination
Percentage of Maternal Participants With Adverse Events (AEs) From the Time of Vaccination Through 1 Month After Vaccination
An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were included in this outcome measure.
Time frame: From vaccination on Day 1 up to 1 month after vaccination
Percentage of Maternal Participants With Adverse Event of Special Interest (AESIs)
AESIs are a subset of targeted medical events based on review of known pharmacology, toxicology findings, possible class effects, published literature, and signals arising from safety data assessments, and on population under study. AESIs were based on targeted medical events associated with pregnant maternal participants prior to/during delivery and post delivery. For maternal participants, the following were considered as protocol defined AESIs: diagnosis of Guillain-Barré syndrome; diagnosis of acute polyneuropathy without an underlying etiology; hypertensive disorders of pregnancy; preterm delivery (delivery at \<37 0/7 weeks' gestation) and atrial fibrillation. AESIs was to be recorded as an AE or serious adverse event (SAE) on the case report form (CRF).
Time frame: From vaccination on Day 1 up to 6 months after delivery (up to maximum of 10 months)
Percentage of Maternal Participants With SAEs From Vaccination Throughout the Study
An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE was any untoward medical occurrence that at any dose: resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, resulted in congenital anomaly/birth defect or that was considered an important medical event.
Time frame: From vaccination on Day 1 up to 6 months after delivery (up to maximum of 10 months)
Percentage of Infant Participants With AESIs From Birth Through 6 Months of Age
AESIs are a subset of targeted medical events based on review of known pharmacology, toxicology findings, possible class effects, published literature, and signals arising from safety data assessments, and on population under study. AESIs were based on targeted medical events associated with infants at birth. For infant participants the following were considered as protocol defined AESIs: preterm birth (born at \<37 0/7 week's gestation); birth weight 1001-2500 grams (g); developmental delay. Extremely preterm birth (born at \<28 0/7 week's gestation) and extremely low birth weight (less than or equal to \[\<=\] 1000 g) were reported as serious AESIs.
Time frame: From birth up to 6 months of age
Number of Infant Participants With Reported Neonatal Deaths From Birth Through 1 Months of Age
Neonatal death was defined as the death of a live-born infant that occurred within a month after birth.
Time frame: Within 1 Month after birth
Number of Infant Participants With Congenital Malformations/Anomalies at Birth
Congenital malformations/anomalies were defined as structural or functional anomalies that occurred during intrauterine life and could be identified prenatally, at birth or later in life.
Time frame: At birth
Number of Infant Participants With Other Neonatal Problems at Birth
Other neonatal problem included dysmaturity, neonatal illness, hospitalization, and drug therapies.
Time frame: At birth
Number of Infant Participants According to Appearance, Pulse, Grimace, Activity, and Respiration (APGAR) Score at 1 Minute After Birth
APGAR was a fast evaluation technique used to evaluate a newborn baby's overall health. APGAR stands for (A) Appearance (skin coloration), (P) Pulse (heart rate), (G) Grimace (reflex response), (A) Activity (muscle tone) and (R) Respiration (breathing). Each component was given a score of 0, 1, or 2; after summing up scores for each component a total possible score was of 0 (worst condition) to 10 (best condition), where higher scores indicate better health. A score of 7 to 10 was good, 4 to \<7 was moderate, and \<4 was poor.
Time frame: 1 minute after birth
Number of Infant Participants According to APGAR Score at 5 Minutes After Birth
APGAR was a fast evaluation technique used to evaluate a newborn baby's overall health. APGAR stands for (A) Appearance (skin coloration), (P) Pulse (heart rate), (G) Grimace (reflex response), (A) Activity (muscle tone) and (R) Respiration (breathing). Each component was given a score of 0, 1, or 2; after summing up scores for each component a total possible score was of 0 (worst condition) to 10 (best condition), where higher scores indicate better health. A score of 7 to 10 was good, 4 to \<7 was moderate, and \<4 was poor.
Time frame: 5 minutes after birth
Number of Infant Participants According to APGAR Score at 10 Minutes After Birth
APGAR was a fast evaluation technique used to evaluate a newborn baby's overall health. APGAR stands for (A) Appearance (skin coloration), (P) Pulse (heart rate), (G) Grimace (reflex response), (A) Activity (muscle tone) and (R) Respiration (breathing). Each component was given a score of 0, 1, or 2; after summing up scores for each component a total possible score was of 0 (worst condition) to 10 (best condition), where higher scores indicate better health. A score of 7 to 10 was good, 4 to \<7 was moderate, and \<4 was poor.
Time frame: 10 minutes after birth
Number of Infant Participants According to Gestational Age (GA) at Birth
GA at birth was collected as:\>=24 to \<28 weeks, \>=28 to \<34 weeks, \>=34 to \<37 weeks, \>=37 to \<42 weeks, and \>=42 weeks.
Time frame: At birth
Number of Infant Participants Requiring Hospitalization at Birth
Length of hospitalization at birth refers to the amount of time the infant remains admitted to the healthcare facility immediately following delivery and if that length of time is greater than or less than 72 hours. Postnatal standard of care procedures in South Africa were as follows: healthy newborns and their mothers were typically discharged within 24 hours after an uncomplicated vaginal delivery, or within 72 hours following an uncomplicated Caesarean section. These practices were supported by the Guidelines for Maternity Care in South Africa.
Time frame: From birth until discharge from hospitalization (up to a maximum of 72 hours)
Percentage of Infant Participants With AEs From Birth to 1 Month of Age
An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Time frame: From birth to 1 month of age
Percentage of Infant Participants With SAEs From Birth Through 6 Months of Age
An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE was any untoward medical occurrence that at any dose: resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, resulted in congenital anomaly/birth defect or that was considered an important medical event.
Time frame: From birth to 6 months of age
Percentage of Infant Participants With Newly Diagnosed Chronic Medical Conditions (NDCMCs) From Birth Through 6 Months of Age
An NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects. NDCMCs were reported as both AEs and SAEs.
Time frame: From birth to 6 months of age
Geometric Mean Titer (GMT) of Neutralizing Titer (NTs) for Respiratory Syncytial Virus Subgroup A (RSV A) and Respiratory Syncytial Virus Subgroup B (RSV B) Before Vaccination and at Delivery: Maternal Participants
GMTs and the corresponding 2-sided 95% confidence intervals (CIs) were calculated by exponentiating the mean logarithm of the neutralizing titers and the corresponding CIs based on the Student t distribution.
Time frame: Before vaccination on Day 1 and at delivery
Geometric Mean Fold Rise (GMFR) of NTs for RSV A and RSV B From Before Vaccination to Delivery: Maternal Participants
GMFRs and the corresponding 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the fold rises and the corresponding CIs based on the Student t distribution. The GMFR for each vaccine group was defined as the geometric mean of the fold rises in the assay results from the specified time points.
Time frame: Before vaccination on Day 1 to delivery
| Milestone | Maternal Participants: RSVpreF | Maternal Participants: Placebo | Infant Participants: RSVpreF | Infant Participants: Placebo |
|---|---|---|---|---|
| Started | 172 | 171 | 171 | 167 |
| Safety population | 172 | 170 | 171 | 166 |
| Completed | 167 | 163 | 165 | 158 |
| Not completed | 5 | 8 | 6 | 9 |
| Withdrew: Death | 1 | 2 | 1 | 3 |
| Withdrew: Lost to follow-up | 3 | 3 | 4 | 2 |
| Withdrew: Protocol deviation | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 2 | 0 | 0 |
| Withdrew: Withdrawal by parent/guardian | 0 | 0 | 1 | 2 |
| Withdrew: Other | 0 | 0 | 0 | 2 |
Local reactions included redness, swelling, and pain at injection site and were recorded in electronic diary (e-diary). Redness and swelling were measured by the maternal participant and recorded in measuring device units (mdu) in the e-diary (range: 1 to 21). 1 mdu = 0.5 centimetre (cm). Redness and swelling were graded as mild (\>2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm), severe (\>10.0 cm) and grade 4 (necrosis or exfoliative dermatitis for redness and necrosis for swelling). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and grade 4 (emergency room visit or hospitalization for severe pain at the injection site). Grade 4 reactions were classified by the investigator or medically qualified designee.
| Percentage of participants | Maternal Participants: RSVpreF | Maternal Participants: Placebo |
|---|---|---|
| Redness: Any | 1.8 (0.4 to 5.3) | 1.8 (0.4 to 5.2) |
| Redness: Mild | 0 (0.0 to 2.2) | 1.2 (0.1 to 4.3) |
| Redness: Moderate | 1.8 (0.4 to 5.3) | 0.6 (0.0 to 3.3) |
| Redness: Severe | 0 (0.0 to 2.2) | 0 (0.0 to 2.2) |
| Swelling: Any | 2.5 (0.7 to 6.2) | 2.4 (0.7 to 6.1) |
| Swelling: Mild | 0.6 (0.0 to 3.4) | 1.2 (0.1 to 4.3) |
| Swelling: Moderate | 1.8 (0.4 to 5.3) | 0.6 (0.0 to 3.3) |
| Swelling: Severe | 0 (0.0 to 2.2) | 0.6 (0.0 to 3.3) |
| Pain at injection site: Any | 27.0 (20.3 to 34.5) | 17.5 (12.0 to 24.1) |
| Pain at injection site: Mild | 20.9 (14.9 to 27.9) | 11.4 (7.0 to 17.3) |
| Pain at injection site: Moderate | 6.1 (3.0 to 11.0) | 5.4 (2.5 to 10.0) |
| Pain at injection site: Severe | 0 (0.0 to 2.2) | 0.6 (0.0 to 3.3) |
Systemic events included fever, fatigue, headache, nausea, muscle pain, joint pain, vomiting and diarrhea and were recorded by participants in the e-diary. Fever was defined as an oral temperature greater than or equal to (\>=) 38.0 degree Celsius (C) and classified as mild (38.0 to 38.4 degree C), moderate (38.5 to 38.9 degree C), severe (39.0 to 40.0 degree C) and grade 4 (\>40.0 degree C). Headache, nausea, fatigue, muscle pain and joint pain were graded as mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily activity). Vomiting: mild (1-2 times in 24 hours \[H\]), moderate (\>2 times in 24 H), severe (required intravenous \[IV\] hydration). Diarrhea: mild (2-3 loose stools in 24 H), moderate (4-5 loose stools in 24 H), severe (\>=6 loose stools in 24 H). For all systemic events except fever, Grade 4= emergency room visit or hospitalization. Grade 4 events were classified by investigator or medically qualified designee.
| Percentage of participants | Maternal Participants: RSVpreF | Maternal Participants: Placebo |
|---|---|---|
| Fever: >=38.0 degree C | 3.1 (1.0 to 7.0) | 1.8 (0.4 to 5.2) |
| Fever: 38.0 to 38.4 degree C | 1.8 (0.4 to 5.3) | 0.6 (0.0 to 3.3) |
| Fever: 38.5 to 38.9 degree C | 1.2 (0.1 to 4.4) | 0.6 (0.0 to 3.3) |
| Fever: 39.0 to 40.0 degree C | 0 (0.0 to 2.2) | 0.6 (0.0 to 3.3) |
| Fever: >40.0 degree C | 0 (0.0 to 2.2) | 0 (0.0 to 2.2) |
| Fatigue: Any | 35.0 (27.7 to 42.8) | 41.6 (34.0 to 49.5) |
| Fatigue: Mild | 20.9 (14.9 to 27.9) | 26.5 (20.0 to 33.9) |
| Fatigue: Moderate | 13.5 (8.7 to 19.7) | 13.9 (9.0 to 20.1) |
| Fatigue: Severe | 0.6 (0.0 to 3.4) | 1.2 (0.1 to 4.3) |
| Headache: Any | 33.1 (26.0 to 40.9) | 31.9 (24.9 to 39.6) |
| Headache: Mild | 21.5 (15.4 to 28.6) | 22.3 (16.2 to 29.4) |
| Headache: Moderate | 11.7 (7.2 to 17.6) | 8.4 (4.7 to 13.7) |
| Headache: Severe | 0 (0.0 to 2.2) | 1.2 (0.1 to 4.3) |
| Nausea: Any | 20.2 (14.4 to 27.2) | 17.5 (12.0 to 24.1) |
| Nausea: Mild | 17.2 (11.7 to 23.9) | 13.9 (9.0 to 20.1) |
| Nausea: Moderate | 3.1 (1.0 to 7.0) | 3.6 (1.3 to 7.7) |
| Nausea: Severe | 0 (0.0 to 2.2) | 0 (0.0 to 2.2) |
| Muscle pain: Any | 25.2 (18.7 to 32.5) | 14.5 (9.5 to 20.7) |
| Muscle pain: Mild | 17.2 (11.7 to 23.9) | 6.6 (3.4 to 11.5) |
| Muscle pain: Moderate | 8.0 (4.3 to 13.3) | 7.2 (3.8 to 12.3) |
| Muscle pain: Severe | 0 (0.0 to 2.2) | 0.6 (0.0 to 3.3) |
| Joint pain: Any | 16.6 (11.2 to 23.2) | 13.3 (8.5 to 19.4) |
| Joint pain: Mild | 11.0 (6.7 to 16.9) | 7.8 (4.2 to 13.0) |
| Joint pain: Moderate | 5.5 (2.6 to 10.2) | 5.4 (2.5 to 10.0) |
| Joint pain: Severe | 0 (0.0 to 2.2) | 0 (0.0 to 2.2) |
| Vomiting: Any | 12.9 (8.2 to 19.0) | 13.3 (8.5 to 19.4) |
| Vomiting: Mild | 9.8 (5.7 to 15.5) | 10.2 (6.1 to 15.9) |
| Vomiting: Moderate | 3.1 (1.0 to 7.0) | 3.0 (1.0 to 6.9) |
| Vomiting: Severe | 0 (0.0 to 2.2) | 0 (0.0 to 2.2) |
| Diarrhea: Any | 9.8 (5.7 to 15.5) | 9.6 (5.6 to 15.2) |
| Diarrhea: Mild | 6.1 (3.0 to 11.0) | 7.8 (4.2 to 13.0) |
| Diarrhea: Moderate | 3.1 (1.0 to 7.0) | 1.8 (0.4 to 5.2) |
| Diarrhea: Severe | 0.6 (0.0 to 3.4) | 0 (0.0 to 2.2) |
An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were included in this outcome measure.
| Percentage of participants | Maternal Participants: RSVpreF | Maternal Participants: Placebo |
|---|---|---|
| Percentage of Maternal Participants With Adverse Events (AEs) From the Time of Vaccination Through 1 Month After Vaccination | 14.5 (9.6 to 20.7) | 24.1 (17.9 to 31.3) |
AESIs are a subset of targeted medical events based on review of known pharmacology, toxicology findings, possible class effects, published literature, and signals arising from safety data assessments, and on population under study. AESIs were based on targeted medical events associated with pregnant maternal participants prior to/during delivery and post delivery. For maternal participants, the following were considered as protocol defined AESIs: diagnosis of Guillain-Barré syndrome; diagnosis of acute polyneuropathy without an underlying etiology; hypertensive disorders of pregnancy; preterm delivery (delivery at \<37 0/7 weeks' gestation) and atrial fibrillation. AESIs was to be recorded as an AE or serious adverse event (SAE) on the case report form (CRF).
| Percentage of participants | Maternal Participants: RSVpreF | Maternal Participants: Placebo |
|---|---|---|
| Percentage of Maternal Participants With Adverse Event of Special Interest (AESIs) | 14.0 (9.1 to 20.0) | 13.5 (8.8 to 19.6) |
An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE was any untoward medical occurrence that at any dose: resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, resulted in congenital anomaly/birth defect or that was considered an important medical event.
| Percentage of participants | Maternal Participants: RSVpreF | Maternal Participants: Placebo |
|---|---|---|
| Percentage of Maternal Participants With SAEs From Vaccination Throughout the Study | 34.9 (27.8 to 42.5) | 33.5 (26.5 to 41.2) |
AESIs are a subset of targeted medical events based on review of known pharmacology, toxicology findings, possible class effects, published literature, and signals arising from safety data assessments, and on population under study. AESIs were based on targeted medical events associated with infants at birth. For infant participants the following were considered as protocol defined AESIs: preterm birth (born at \<37 0/7 week's gestation); birth weight 1001-2500 grams (g); developmental delay. Extremely preterm birth (born at \<28 0/7 week's gestation) and extremely low birth weight (less than or equal to \[\<=\] 1000 g) were reported as serious AESIs.
| Percentage of participants | Infant Participants: RSVpreF | Infant Participants: Placebo |
|---|---|---|
| Percentage of Infant Participants With AESIs From Birth Through 6 Months of Age | 16.4 (11.2 to 22.8) | 17.5 (12.0 to 24.1) |
Neonatal death was defined as the death of a live-born infant that occurred within a month after birth.
| Participants | Infant Participants: RSVpreF | Infant Participants: Placebo |
|---|---|---|
| Number of Infant Participants With Reported Neonatal Deaths From Birth Through 1 Months of Age | 1 | 3 |
Congenital malformations/anomalies were defined as structural or functional anomalies that occurred during intrauterine life and could be identified prenatally, at birth or later in life.
| Participants | Infant Participants: RSVpreF | Infant Participants: Placebo |
|---|---|---|
| Number of Infant Participants With Congenital Malformations/Anomalies at Birth | 4 | 7 |
Other neonatal problem included dysmaturity, neonatal illness, hospitalization, and drug therapies.
| Participants | Infant Participants: RSVpreF | Infant Participants: Placebo |
|---|---|---|
| Number of Infant Participants With Other Neonatal Problems at Birth | 22 | 20 |
APGAR was a fast evaluation technique used to evaluate a newborn baby's overall health. APGAR stands for (A) Appearance (skin coloration), (P) Pulse (heart rate), (G) Grimace (reflex response), (A) Activity (muscle tone) and (R) Respiration (breathing). Each component was given a score of 0, 1, or 2; after summing up scores for each component a total possible score was of 0 (worst condition) to 10 (best condition), where higher scores indicate better health. A score of 7 to 10 was good, 4 to \<7 was moderate, and \<4 was poor.
| Participants | Infant Participants: RSVpreF | Infant Participants: Placebo |
|---|---|---|
| Score <4 | 0 | 2 |
| Score 4 to <7 | 9 | 10 |
| Score 7 to 10 | 158 | 147 |
APGAR was a fast evaluation technique used to evaluate a newborn baby's overall health. APGAR stands for (A) Appearance (skin coloration), (P) Pulse (heart rate), (G) Grimace (reflex response), (A) Activity (muscle tone) and (R) Respiration (breathing). Each component was given a score of 0, 1, or 2; after summing up scores for each component a total possible score was of 0 (worst condition) to 10 (best condition), where higher scores indicate better health. A score of 7 to 10 was good, 4 to \<7 was moderate, and \<4 was poor.
| Participants | Infant Participants: RSVpreF | Infant Participants: Placebo |
|---|---|---|
| Score <4 | 0 | 0 |
| Score 4 to <7 | 0 | 0 |
| Score 7 to 10 | 165 | 158 |
APGAR was a fast evaluation technique used to evaluate a newborn baby's overall health. APGAR stands for (A) Appearance (skin coloration), (P) Pulse (heart rate), (G) Grimace (reflex response), (A) Activity (muscle tone) and (R) Respiration (breathing). Each component was given a score of 0, 1, or 2; after summing up scores for each component a total possible score was of 0 (worst condition) to 10 (best condition), where higher scores indicate better health. A score of 7 to 10 was good, 4 to \<7 was moderate, and \<4 was poor.
| Participants | Infant Participants: RSVpreF | Infant Participants: Placebo |
|---|---|---|
| Score <4 | 0 | 0 |
| Score 4 to <7 | 0 | 0 |
| Score 7 to 10 | 69 | 64 |
GA at birth was collected as:\>=24 to \<28 weeks, \>=28 to \<34 weeks, \>=34 to \<37 weeks, \>=37 to \<42 weeks, and \>=42 weeks.
| Participants | Infant Participants: RSVpreF | Infant Participants: Placebo |
|---|---|---|
| >=24 weeks to <28 weeks | 0 | 1 |
| >=28 weeks to <34 weeks | 1 | 2 |
| >=34 weeks to <37 weeks | 14 | 10 |
| >=37 weeks to <42 weeks | 155 | 147 |
| >=42 weeks | 1 | 6 |
Length of hospitalization at birth refers to the amount of time the infant remains admitted to the healthcare facility immediately following delivery and if that length of time is greater than or less than 72 hours. Postnatal standard of care procedures in South Africa were as follows: healthy newborns and their mothers were typically discharged within 24 hours after an uncomplicated vaginal delivery, or within 72 hours following an uncomplicated Caesarean section. These practices were supported by the Guidelines for Maternity Care in South Africa.
| Participants | Infant Participants: RSVpreF | Infant Participants: Placebo |
|---|---|---|
| <=72 hours | 136 | 130 |
| > 72 hours | 33 | 33 |
| Not reported | 2 | 3 |
An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
| Percentage of participants | Infant Participants: RSVpreF | Infant Participants: Placebo |
|---|---|---|
| Percentage of Infant Participants With AEs From Birth to 1 Month of Age | 34.5 (27.4 to 42.1) | 44.0 (36.3 to 51.9) |
An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE was any untoward medical occurrence that at any dose: resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, resulted in congenital anomaly/birth defect or that was considered an important medical event.
| Percentage of participants | Infant Participants: RSVpreF | Infant Participants: Placebo |
|---|---|---|
| Percentage of Infant Participants With SAEs From Birth Through 6 Months of Age | 18.7 (13.2 to 25.4) | 21.7 (15.7 to 28.7) |
An NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects. NDCMCs were reported as both AEs and SAEs.
| Percentage of participants | Infant Participants: RSVpreF | Infant Participants: Placebo |
|---|---|---|
| Percentage of Infant Participants With Newly Diagnosed Chronic Medical Conditions (NDCMCs) From Birth Through 6 Months of Age | 1.2 (0.1 to 4.2) | 0.6 (0.0 to 3.3) |
GMTs and the corresponding 2-sided 95% confidence intervals (CIs) were calculated by exponentiating the mean logarithm of the neutralizing titers and the corresponding CIs based on the Student t distribution.
| Titer | Maternal Participants: RSVpreF | Maternal Participants: Placebo |
|---|---|---|
| RSV A: Before vaccination | 1649 (1443.5 to 1884.8) | 1662 (1462.8 to 1889.4) |
| RSV A: At delivery | 13192 (11347.9 to 15336.8) | 1663 (1439.6 to 1920.8) |
| RSV B: Before vaccination | 2242 (1937.9 to 2593.9) | 2075 (1795.8 to 2397.1) |
| RSV B: At delivery | 16424 (13999.2 to 19269.1) | 2297 (1996.1 to 2643.5) |
GMFRs and the corresponding 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the fold rises and the corresponding CIs based on the Student t distribution. The GMFR for each vaccine group was defined as the geometric mean of the fold rises in the assay results from the specified time points.
| Fold rise | Maternal Participants: RSVpreF | Maternal Participants: Placebo |
|---|---|---|
| RSV A | 8.0 (6.83 to 9.36) | 1.0 (0.89 to 1.12) |
| RSV B | 7.3 (6.20 to 8.66) | 1.1 (0.99 to 1.24) |
Collected over Maternal participants: Local reactions and systemic events: From Day 1 to Day 7 after vaccination; SAEs and AESIs: From vaccination on Day 1 up to 6 months after delivery (maximum up to 10 months); Other AEs: From vaccination on Day 1 up to 1 month after vaccination; Infant participants: SAEs, AESIs and NDCMCs: From birth up to 6 months of age; Other AEs: From birth up to 1 month. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Maternal Participants: RSVpreF | 1/172 (0.6%) | 60/172 (34.9%) | 103/172 (59.9%) |
| Maternal Participants: Placebo | 2/170 (1.2%) | 57/170 (33.5%) | 115/170 (67.6%) |
| Infant Participants: RSVpreF | 1/171 (0.6%) | 32/171 (18.7%) | 53/171 (31%) |
| Infant Participants: Placebo | 3/166 (1.8%) | 36/166 (21.7%) | 52/166 (31.3%) |
| Event | Maternal Participants: RSVpreF | Maternal Participants: Placebo | Infant Participants: RSVpreF | Infant Participants: Placebo |
|---|---|---|---|---|
| Foetal distress syndromePregnancy, puerperium and perinatal conditions | 25/172 | 22/170 | 0/171 | 0/166 |
| Pre-eclampsiaPregnancy, puerperium and perinatal conditions | 4/172 | 8/170 | 0/171 | 0/166 |
| Gestational hypertensionPregnancy, puerperium and perinatal conditions | 6/172 | 4/170 | 0/171 | 0/166 |
| Jaundice neonatalPregnancy, puerperium and perinatal conditions | 0/172 | 0/170 | 4/171 | 5/166 |
| Low birth weight babyPregnancy, puerperium and perinatal conditions | 0/172 | 0/170 | 2/171 | 5/166 |
| Premature babyPregnancy, puerperium and perinatal conditions | 0/172 | 0/170 | 3/171 | 5/166 |
| Cephalo-pelvic disproportionPregnancy, puerperium and perinatal conditions | 2/172 | 5/170 | 0/171 | 0/166 |
| Prolonged labourPregnancy, puerperium and perinatal conditions | 5/172 | 0/170 | 0/171 | 0/166 |
| Transient tachypnoea of the newbornRespiratory, thoracic and mediastinal disorders | 0/172 | 0/170 | 0/171 | 4/166 |
| Prolonged pregnancyPregnancy, puerperium and perinatal conditions | 1/172 | 4/170 | 0/171 | 0/166 |
| Event | Maternal Participants: RSVpreF | Maternal Participants: Placebo | Infant Participants: RSVpreF | Infant Participants: Placebo |
|---|---|---|---|---|
| Fatigue (FATIGUE)General disorders | 57/163 | 69/166 | 0/171 | 0/166 |
| Headache (HEADACHE)Nervous system disorders | 54/163 | 53/166 | 0/171 | 0/166 |
| Injection site pain (PAIN AT INJECTION SITE)General disorders | 44/163 | 29/166 | 0/171 | 0/166 |
| Myalgia (MUSCLE PAIN)Musculoskeletal and connective tissue disorders | 41/163 | 24/166 | 0/171 | 0/166 |
| Nausea (NAUSEA)Gastrointestinal disorders | 33/163 | 29/166 | 0/171 | 0/166 |
| Arthralgia (JOINT PAIN)Musculoskeletal and connective tissue disorders | 27/163 | 22/166 | 0/171 | 0/166 |
| Vomiting (VOMITING)Gastrointestinal disorders | 21/163 | 22/166 | 0/171 | 0/166 |
| Low birth weight babyPregnancy, puerperium and perinatal conditions | 0/172 | 0/170 | 21/171 | 16/166 |
| Diarrhoea (DIARRHEA)Gastrointestinal disorders | 16/163 | 16/166 | 0/171 | 0/166 |
| Premature babyPregnancy, puerperium and perinatal conditions | 0/172 | 0/170 | 12/171 | 8/166 |
Maternal safety population included all randomized maternal participants who received at least 1 dose of the study intervention. Infant safety population included all infant participants who were born to vaccinated maternal participants.
| Age, Customized(Participants) | Maternal Participants: RSVpreF | Maternal Participants: Placebo | Infant Participants: RSVpreF | Infant Participants: Placebo | Total |
|---|---|---|---|---|---|
| <16 years | 0 | 0 | 171 | 166 | 337 |
| Between 16 and 44 years | 172 | 170 | 0 | 0 | 342 |
| Sex: Female, Male(Participants) | Maternal Participants: RSVpreF | Maternal Participants: Placebo | Infant Participants: RSVpreF | Infant Participants: Placebo | Total |
|---|---|---|---|---|---|
| Female | 172 | 170 | 80 | 75 | 497 |
| Male | 0 | 0 | 91 | 91 | 182 |
| Ethnicity (NIH/OMB)(Participants) | Maternal Participants: RSVpreF | Maternal Participants: Placebo | Infant Participants: RSVpreF | Infant Participants: Placebo | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 145 | 149 | 168 | 162 | 624 |
| Unknown or Not Reported | 27 | 21 | 3 | 4 | 55 |
| Race (NIH/OMB)(Participants) | Maternal Participants: RSVpreF | Maternal Participants: Placebo | Infant Participants: RSVpreF | Infant Participants: Placebo | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 171 | 169 | 170 | 166 | 676 |
| White | 0 | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 1 | 1 | 0 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Mar 2024 to primary completion in Jun 2025, 14 months.
Results were first posted in Jul 2026, 1 year after primary completion.
Of 41 phase 3 interventional studies under Respiratory Tract Infections, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 73. This study's 14 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Abrysvo
Respiratory Tract Infections →